{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-21-003522","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2021-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.490623+00:00","generated_at":"2026-06-29T11:20:10.942608+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement","bullets":["Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.","R&D expenses rose 70.4% to $0.5M, driven by XCART spending.","Received ~$0.3M in royalty payments from Takeda sublicense in Q2.","Completed $12.5M private placement in August 2021, net proceeds ~$11.4M.","Advancing XCART personalized CAR T platform toward IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-21-003522","json":"https://secwatch.observer/filing/0001683168-21-003522.json","markdown":"https://secwatch.observer/filing/0001683168-21-003522.md","text":"https://secwatch.observer/filing/0001683168-21-003522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/0001683168-21-003522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316821003522/xenetic_i8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T11:20:10.942608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}